No Picture
News

GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies

MEMPHIS, Tenn. & SAN DIEGO–(BUSINESS WIRE)–GTx, Inc. (Nasdaq: GTXI) and?Oncternal Therapeutics, Inc., a privately held clinical-stage biotechnology company developing potential first-in-class therapeutic candidates for cancers with critical unmet… […]

No Picture
News

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]

No Picture
News

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]

No Picture
News

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]

No Picture
News

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Searching for a bigger spot for itself in the global market weeks after becoming the first Chinese biotech to nab an FDA ?breakthrough? designation, BeiGene has enlisted the protein engineers at Ambrx to add some discovery projects to its cancer pipeli… […]